Photo: Siraj Ahmad/Shutterstock
Brazilian health regulator Anvisa has approved new phase 2 and 3 clinical trials for a potential vaccine developed by Chinese firm Sichuan Clover Biopharmaceuticals. The decision was made on Friday and published today.
The study will use up to 30,000 volunteers from countries in Latin America, Europe, Asia, and Africa. Roughly 12,100 participants will come from Brazil, specifically from the states of Rio Grande do Sul, Rio de Janeiro, and Rio Grande do Norte.
This will be the sixth Covid-19 vaccine clinical trial approved in Brazil — after those of AstraZeneca, Sinovac, Pfizer, Johnson & Johnson, and Medicago-GSK.
The specialization trend among corporate board members It is not only a matter of perception:…
Panama will hold its presidential elections on Sunday, months after huge protests saw thousands descend…
The city of Rio de Janeiro estimates that a Madonna concert this Saturday on Copacabana…
Latin America’s trend of banning opposition candidates from elections has caught on in an ever-growing…
The São Paulo City Council on Thursday approved legislation authorizing Brazil’s largest city to sign…
The preliminary report on AI regulations presented to Brazil’s Senate last week provides a middle-of-the-road…